SCHEMBL1194334

SCHEMBL1194334

O=C(O)COc1cccc2c1[nH]c1ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.58
KDM4E B2RXH2 1/20 0.58
HPGD P15428 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.49
POLB P06746 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
GLA P06280 1/20 0.49
PTGDR2 Q9Y5Y4 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
MAPT P10636 2/20 0.44
SRD5A2 P31213 1/20 0.44
KIF11 P52732 1/20 0.44
JAK2 O60674 1/20 0.43
TP53 P04637 1/20 0.43
HTT P42858 1/20 0.43
KLK7 P49862 1/20 0.43
ALOX15 P16050 1/20 0.43
PBRM1 Q86U86 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17950801 0.82 KDM4E (0.58) ALDH1A1KDM4EHPGDTDP1L3MBTL1
SCHEMBL8391232 0.80 MAPT (0.48) ALDH1A1KDM4EHPGDTDP1L3MBTL1
SCHEMBL15560416 0.80 KIF11 (0.47) ALDH1A1KDM4EHPGDL3MBTL1POLB
SCHEMBL7813205 0.79 MAPT (0.46) ALDH1A1KDM4EL3MBTL1POLBMEN1
SCHEMBL7149142 0.78 KDM4E (0.47) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL27777168 0.78 SRD5A2 (0.56) TDP1L3MBTL1MAPTSRD5A2KIF11
SCHEMBL5018077 0.78 KIF11 (0.53) ALDH1A1KDM4EHPGDMEN1KMT2A
SCHEMBL27500727 0.78 PARP14 (0.49) ALDH1A1MAPTKIF11JAK2TP53
SCHEMBL29030454 0.77 MCL1 (0.44) ALDH1A1KDM4EMAPTKIF11JAK2
SCHEMBL5796179 0.77 MEN1 (0.39) ALDH1A1KDM4EHPGDTDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2247558-B2 NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION LILLY CO ELI (US) 2024-07-03 EP disclosed
EP-2247558-B1 NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION LILLY CO ELI (US) 2022-02-02 EP disclosed
EP-2852572-B1 CARBOLINE AND CARBAZOLE BASED IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION LILLY CO ELI (US) 2020-04-01 EP disclosed
CN-107011342-A The preparation based on carboline and carbazole for detecting neurological dysfunction 伊莱利利公司 2017-08-04 CN disclosed
CN-104781234-A Carboline and carbazole based imaging agents for detecting neurological dysfunction LILLY CO ELI 2015-07-15 CN disclosed
US-20150030540-A1 Imaging agents for detecting neurological dysfunction LILLY CO ELI (US) 2015-01-29 US disclosed
US-8932557-B2 Imaging agents for detecting neurological dysfunction ELI LILLY AND COMPANY (US) 2015-01-13 US disclosed
EP-2599763-A1 Novel imaging agents for detecting neurological dysfunction Siemens Molecular Imaging, Inc. (US) 2013-06-05 EP disclosed
US-20120302755-A1 Imaging Agents for Detecting Neurological Dysfunction SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2012-11-29 US disclosed
US-8318132-B2 Imaging agents for detecting neurological dysfunction SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2012-11-27 US disclosed
US-20110091382-A1 NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION SIEMENS MEDICAL SOLUTION USA, INC. 2011-04-21 US disclosed
US-20110046378-A1 Novel Imaging Agents for Detecting Neurological Dysfunction SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2011-02-24 US disclosed
EP-2247558-A1 NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION Siemens Medical Solutions USA, Inc. (US) 2010-11-10 EP disclosed
WO-2009102498-A1 NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110091382-A1 NOVEL IMAGING AGENTS FOR DETECTING NEUROLOGICAL DYSFUNCTION FABP7, TSPO, SLC18A3 ALDH1A1 3134/4885KDM4E 4183/4885HPGD 1897/4885
US-20110046378-A1 Novel Imaging Agents for Detecting Neurological Dysfunction FABP7, SLC18A3, TSPO ALDH1A1 3189/4885KDM4E 4258/4885HPGD 1948/4885
US-20150030540-A1 Imaging agents for detecting neurological dysfunction SLC18A3, TSPO, CHAT ALDH1A1 2661/4885KDM4E 4807/4885HPGD 1373/4885
US-20120302755-A1 Imaging Agents for Detecting Neurological Dysfunction SLC18A3, TSPO, CHAT ALDH1A1 2661/4885KDM4E 4807/4885HPGD 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.